Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.56 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.56 |
| ▸ | CHRNG | P07510 | 2/20 | 0.56 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.56 |
| ▸ | CHRND | Q07001 | 2/20 | 0.56 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20809637 | 1.00 | SLC6A2 (0.56) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL26561799 | 0.87 | HSD17B10 (0.47) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL30471336 | 0.86 | CYP2B6 (0.58) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL29018403 | 0.86 | CYP2B6 (0.58) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2599163 | 0.83 | SLC6A2 (0.53) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL15007460 | 0.83 | SLC6A2 (0.53) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL685167 | 0.82 | SLC6A2 (0.60) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL8159886 | 0.82 | SLC6A2 (0.63) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2290370 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL9539804 | 0.81 | PARP1 (0.53) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383683-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383668-B2 | 11-beta-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8153798-B2 | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120010194-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048908-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2239012-A2 | Pharmaceutical use of substituted amides | High Point Pharmaceuticals, LLC (US) | 2010-10-13 | — | — | EP | disclosed |
| EP-1615698-B1 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-05 | — | — | US | disclosed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| EP-1615647-A2 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089367-A1 | PHARMACEUTICAL USE OF SUBSTITUTED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089380-A2 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089471-A2 | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010194-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD11B2, HSD3B1 | SLC6A2 3098/4885SLC6A3 4114/4885CHRNA1 1259/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | SLC6A2 2697/4885SLC6A3 3668/4885CHRNA1 1295/4885 |
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HSD3B1, HSD11B2, HSD3B2 | SLC6A2 3523/4885SLC6A3 3734/4885CHRNA1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.